They scored a victory recently. In November, an FDA advisory panel voted 14-1 against key regulatory aspects of the Clozapine Risk Evaluation and Mitigation Strategy, or REMS. The panel determined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback